CLS-AX demonstrated positive results in the phase 1/2a OASIS clinical trial in neovascular age-related macular degeneration, Clearside Biomedical announced in a press release.
CLS-AX (axitinib injectable suspension) met the trial’s primary endpoint by demonstrating a positive safety profile at all doses and time points in 27 participants in four cohorts. There were no reports of serious adverse events, treatment-emergent adverse events, dose-limiting toxicities, or adverse events related to inflammation, vasculitis or vascular occlusion.
The results include 3-month data from the four